Zhitong Finance App News, Keji Pharmaceutical-B (02171.HK) announced that CT0596, a generic CAR-T cell product targeting BCMA, has been approved by IND from the State Drug Administration to treat patients with recurrent/refractory multiple myeloma (R/R MM). The results of the CT0596 IIT study were presented on a poster at the 2026 European Society of Hematology (EHA) Annual Meeting.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.